I
IO Biotech, Inc. (IOBT)
NMS – Real vaqt narxi. Valyuta: USD
0.05
0.00 (0.00%)
Yopilishda: Apr 6, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
0.05
0.00 (0.00%)
Yopilishda: Apr 6, 2026, 4:00 PM EDT
IO Biotech, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, T-win texnologiya platformasiga asoslangan immunitetni modulyatsiya qiluvchi terapevtik saraton vaktsinalarini ishlab chiqadi. Kompaniyaning etakchi terapevtik saraton vaktsinasi nomzodi IO102-IO103 ni o'z ichiga oladi, u indolin-2,3-dehydrogenase (IDO) va dasturlangan o'lim-ligandi (PD-L1) ni ifoda etadigan o'simta mikro-muhitidagi saraton hujayralari va immunitetni bostiruvchi hujayralarga qaratilgan bo'lib, u melanomani davolash uchun 3-bosqichli klinik sinovda, shuningdek, o'pka, bosh va bo'yin, va melanomani davolash uchun 2-bosqichli klinik sinovda. U, shuningdek, Arginase 1 dan olingan jigarrang peptidni o'z ichiga olgan IO112 mahsulot nomzodini ishlab chiqadi, u Arginase 1 dan olingan epitoplarni tan oladigan T-hujayralariga qaratilgan bo'lib, bu buyrak hujayrali karsinoma, bosh va bo'yin, ko'krak, oshqozon osti bezi, tuxumdon, yo'g'on ichak va prostata saratonlari kabi miyeloid hosil bo'lgan bostiruvchi hujayralarning yuqori darajalari bilan bog'liq bo'lgan davolash qiyin bo'lgan o'smalarda yuqori darajada ifoda etiladigan immunitetni tartibga soluvchi fermentdir. Bundan tashqari, kompaniya qattiq o'smalarni davolash uchun TGFβ1 vaktsinasi bo'lgan IO170 ni ishlab chiqadi. IO Biotech, Inc. 2014 yilda tashkil etilgan va Kopengagendagi, Daniyada joylashgan. 2026 yil 31 martda IO Biotech, Inc. o'zining filiallari bilan birgalikda Delaver okrugi uchun AQSh bankrotlik sudi tomonidan 7-bob bo'yicha ixtiyoriy likvidatsiya arizasini topshirdi.
| Ism | Lavozim |
|---|---|
| Anders Ljungqvist | Founder |
| Dr. Faical Miyara Ph.D. | Chief Business Officer |
| Dr. Mai-Britt Zocca Ph.D. | Founder, President, CEO, Principal Financial Officer & Director |
| Mr. Daniel G. Mannix Ph.D. | Senior Vice President of Regulatory Affairs |
| Mr. Devin Whittemore Smith J.D. | Secretary, General Counsel & Chief Compliance Officer |
| Mr. Eric Faulkner M.B.A., M.Sc. | Chief Technical Officer |
| Ms. Amy B. Sullivan M.B.A. | Principal Accounting Officer & CFO |
| Prof. Inge Marie Svane M.D., Ph.D. | Founder & Clinical Advisor |
| Prof. Mads Hald Andersen M.D., Ph.D. | Co-Founder & Scientific Advisor |
| Prof. Per Thor Straten | Founder |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-31 | 8-K | d87973d8k.htm |
| 2026-02-13 | 8-K | d113832d8k.htm |
| 2026-01-30 | 8-K | d13704d8k.htm |
| 2026-01-21 | 8-K | d26457d8k.htm |
| 2025-12-19 | 8-K | d71494d8k.htm |
| 2025-11-21 | 8-K | d74446d8k.htm |
| 2025-11-18 | 8-K | d59895d8k.htm |
| 2025-11-14 | 10-Q | iobt-20250930.htm |
| 2025-09-29 | 8-K | d940102d8k.htm |
| 2025-08-14 | 8-K | d34608d8k.htm |